Related Experiment Video
Updated: Aug 9, 2026
13:33
Infinium Assay for Large-scale SNP Genotyping Applications
Published on: November 19, 2013
Assessing the cost-effectiveness of pharmacogenomics
D L Veenstra1, M K Higashi, K A Phillips
1Pharmaceutical Outcomes Research and Policy Program and Public Health Genetics Program, University of Washington, Department of Pharmacy, Seattle, WA 98195, USA. veenstra@u.washington.edu
AAPS Pharmsci
|December 14, 2001
Summary
Pharmacogenomics can personalize drug therapy for better effectiveness and fewer side effects. A new framework helps evaluate its cost-effectiveness for wider clinical use.
Area of Science:
- Pharmacogenomics
- Health Economics
- Clinical Pharmacology
Background:
- Personalized medicine through pharmacogenomics promises improved drug efficacy and reduced adverse events.
- Current understanding of cost-effectiveness for pharmacogenomic strategies is limited, hindering research and clinical adoption.
Purpose of the Study:
- To develop a framework for evaluating the cost-effectiveness of pharmacogenomic strategies.
- To guide researchers, clinical trial designers, and healthcare providers in decision-making.
Main Methods:
- Review of cost-effectiveness analysis principles and pharmacogenomics.
- Identification of key characteristics influencing pharmacogenomic cost-effectiveness.
- Application of the framework to evaluate specific pharmacogenomic examples.
Main Results:
- Five key characteristics enhance pharmacogenomic cost-effectiveness: severe consequences avoided, difficult current monitoring, strong genotype-phenotype link, rapid/inexpensive testing, and common gene variants.
- Pharmacogenomics demonstrates significant potential for cost-effective health improvements.
Conclusions:
- Pharmacogenomic strategies can be cost-effective and improve patient outcomes.
- Case-by-case evaluation is crucial before widespread implementation and reimbursement decisions.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...